Abstract: A bifurcated stent graft includes a stent graft body that defines exactly one main body opening and at least two exit openings. The stent graft body includes at least one stent attached to a graft fabric material, and includes a dividing wall that divides a combined flow path, into a first flow path and a second flow path that each terminate at one of the respective exit openings. The dividing wall includes a thickness profile that terminates at a leading edge radius that extends across a width of the combined flow path.

Abstract: A bifurcated stent graft includes a stent graft body that defines exactly one main body opening and two exit openings. The stent graft body includes at least one stent attached to a graft fabric material, and includes a dividing wall that divides a combined flow path, into a first flow path and a second flow path that each terminate at one of the respective exit openings. The dividing wall includes a thickness profile that is equal to or thinner than a wall thickness of the graft fabric material, terminates a leading rounded surface, and extends across a width of the combined flow path.

Abstract: A system includes a medical device having a proximal end, a distal end, and a section of material between the proximal and distal ends. The system also includes a vascular force reduction system positioned along the section, including at least one support structure supporting at least one rotating assembly, the at least one rotating assembly having a vessel contact surface, wherein the at least one rotating assembly is configured to rotate substantially toward the proximal and the distal ends of the medical device.

Abstract: A medical device for controlling a release of bioactive agents to a body of patient. The medical device includes a support structure and a coating disposed at least partially covering the support structure. The coating includes a biodegradable outer and inner layer. First beads are disposed between the layers. A therapeutically effective amount of a first bioactive agent is disposed within pores of the first beads. Second beads are disposed between the support structure and the inner layer. A therapeutically effective amount of a second bioactive agent is disposed within the pores of the second beads. The first beads are releasable in response to at least partial biodegradation of the outer layer, and the second beads are releasable after the first beads in response to at least partial biodegradation of the inner layer. The coating may include a nonwoven matrix.

Abstract: A bifurcated stent graft includes a stent graft body that defines exactly one main body opening and at least two exit openings. The stent graft body includes at least one stent attached to a graft fabric material, and includes a dividing wall that divides a combined flow path, into a first flow path and a second flow path that each terminate at one of the respective exit openings. The dividing wall includes a thickness profile that terminates at a leading edge radius that extends across a width of the combined flow path.

Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.